Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2020-02-10 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Q3FY20 Earnings Call on 13th February, 2020
Regulatory Filings
2020-02-10 English
Trading Window
Regulatory Filings Classification · 100% confidence The document contains only a placeholder for a picture and no textual content or substantive information. It is extremely short (54 characters) and does not provide any report, announcement, or detailed information. Given the lack of content, it cannot be classified as any specific report or announcement type. According to the rules, such minimal content defaults to Regulatory Filings (RNS) as a fallback category.
2020-02-04 English
Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on February 12, 2020, inter alia, to consider the following items of business: ....
Regulatory Filings
2020-02-03 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 100% confidence The document text contains only a placeholder for a picture and no substantive content or text. The true document length is only 54 characters, indicating it is extremely short and contains no report or announcement details. There is no financial data, no regulatory references, no meeting information, no voting results, no management or board information, no legal or capital updates, and no other content to classify under any specific filing category. Given the lack of content, the document cannot be classified as a report or announcement type and defaults to the fallback category for miscellaneous filings that do not fit elsewhere, which is Regulatory Filings (RNS).
2020-02-03 English
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2020 ,inter alia, to consider and approve 1. Approval of the unaudited ....
Regulatory Filings
2020-02-03 English
Allotment of ESOP/ESPS
Regulatory Filings Classification · 100% confidence The document text is extremely short (59 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, report content, or any announcement text. Given the lack of any meaningful information, the document cannot be classified as a report or announcement type. According to the rules, such minimal content defaults to Regulatory Filings (RNS) as a fallback category.
2020-01-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.